Atumelnant CRN04894 (ACTH antagonist)

June 02, 2026 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced it will present six abstracts at the Endocrine Society’s ENDO 2026 meeting (June 13–16, 2026; Chicago), highlighting its commercial acromegaly therapy PALSONIFY™ (paltusotine) and investigational ACTH receptor antagonist atumelnant (CRN04894).

For PALSONIFY in acromegaly, an oral presentation will report up to two years of efficacy plus pooled safety from the PATHFNDR-1 and PATHFNDR-2 open-label extension studies. Additional posters will cover (1) long-term safety/efficacy of paltusotine combined with cabergoline (ACROBAT Advance) and (2) real-world biochemical control using U.S. claims and lab data to characterize unmet need.

For atumelnant, two oral presentations will include full Phase 2 results in congenital adrenal hyperplasia (including lowering glucocorticoid doses with sustained androgen reduction) and interim Phase 1b/2a data in ACTH-dependent Cushing’s syndrome using a “block-and-replace” approach; a rapid-fire/poster will present model-informed dose selection for a Phase 3 CAH study.

Business significance: the program emphasizes post-approval evidence-building for PALSONIFY and late-stage clinical momentum for atumelnant across ACTH-excess disorders.